{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Digomann D"],"funding":["Jung Stiftung","Deutsche Forschungsgemeinschaft","Else Kröner-Fresenius-Stiftung","Monika Kutzner Stiftung"],"pagination":["2326"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10136841"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(8)"],"pubmed_abstract":["Immunotherapy has shown promising results in multiple solid tumors and hematological malignancies. However, pancreatic ductal adenocarcinoma (PDAC) has been largely refractory to current clinical immunotherapies. The V-domain Ig suppressor of T-cell activation (VISTA) inhibits T-cell effector function and maintains peripheral tolerance. Here, we determine VISTA expression in nontumorous pancreatic (<i>n</i> = 5) and PDAC tissue using immunohistochemistry (<i>n</i> = 76) and multiplex immunofluorescence staining (<i>n</i> = 67). Additionally, VISTA expression on tumor-infiltrating immune cells and matched blood samples (<i>n</i> = 13) was measured with multicolor flow cytometry. Further, the effect of recombinant VISTA on T-cell activation was investigated in vitro, and VISTA blockade was t"],"journal":["Cancers"],"pubmed_title":["VISTA Ligation Reduces Antitumor T-Cell Activity in Pancreatic Cancer."],"pmcid":["PMC10136841"],"funding_grant_id":["SE2980/5-1","NA"],"pubmed_authors":["Strack J","Distler M","Plesca I","Reiche C","Seifert L","Beer C","Schmitz M","Digomann D","Seifert AM","Heiduk M","Sommer U","Rupp L","Nicolaus S","Weitz J"],"additional_accession":[]},"is_claimable":false,"name":"VISTA Ligation Reduces Antitumor T-Cell Activity in Pancreatic Cancer.","description":"Immunotherapy has shown promising results in multiple solid tumors and hematological malignancies. However, pancreatic ductal adenocarcinoma (PDAC) has been largely refractory to current clinical immunotherapies. The V-domain Ig suppressor of T-cell activation (VISTA) inhibits T-cell effector function and maintains peripheral tolerance. Here, we determine VISTA expression in nontumorous pancreatic (<i>n</i> = 5) and PDAC tissue using immunohistochemistry (<i>n</i> = 76) and multiplex immunofluorescence staining (<i>n</i> = 67). Additionally, VISTA expression on tumor-infiltrating immune cells and matched blood samples (<i>n</i> = 13) was measured with multicolor flow cytometry. Further, the effect of recombinant VISTA on T-cell activation was investigated in vitro, and VISTA blockade was t","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Apr","modification":"2025-04-22T05:15:21.046Z","creation":"2025-04-05T21:16:36.855Z"},"accession":"S-EPMC10136841","cross_references":{"pubmed":["37190254"],"doi":["10.3390/cancers15082326"]}}